Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/bcr-2021-244125 http://scihub22266oqcxt.onion/10.1136/bcr-2021-244125 34330729!8327820!34330729     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34330729&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       BMJ+Case+Rep 2021 ; 14 (7): ? Nephropedia Template TP {{tp|p=34330729|t=2021. Guillain-Barre syndrome after COVID-19 vaccination |pdf=|usr=}}{{34330729}} gab.com Text Guillain-Barre syndrome after COVID-19 vaccination JO: BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=34330729 #FOAvip We report a case of Guillain-Barre syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca). Thus far, there has been no evidence of an increased risk of GBS resulting from either COVID-19 infection nor from COVID-19 vaccines; however, individual cases and population cohorts should be scrutinised, in order to ensure the constant evaluation of such risks. It is as yet not possible to draw conclusions about any significant association between COVID-19 vaccination and GBS. A temporal correlation does not imply, and should not be deemed to signify, causality. However, it is important to remain vigilant, so that any potential increased risk is properly evaluated. The specific presentation of bifacial weakness as the initial symptom may be a characteristic feature of GBS in the context of recent COVID-19 vaccination. Twit Text FOAVip Guillain-Barre syndrome after COVID-19 vaccination ????BMJ Case Rep http://www.kidney.de/pget.php?&tw=1&pmid=34330729 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34330729 #FOAvip English Wikipedia <ref>{{Cite pmid|34330729}}</ref> Guillain-Barre syndrome after COVID-19 vaccination #MMPMID34330729 McKean N; Chircop C BMJ Case Rep 2021[Jul]; 14 (7): ? PMID34330729show ga We report a case of Guillain-Barre syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca). Thus far, there has been no evidence of an increased risk of GBS resulting from either COVID-19 infection nor from COVID-19 vaccines; however, individual cases and population cohorts should be scrutinised, in order to ensure the constant evaluation of such risks. It is as yet not possible to draw conclusions about any significant association between COVID-19 vaccination and GBS. A temporal correlation does not imply, and should not be deemed to signify, causality. However, it is important to remain vigilant, so that any potential increased risk is properly evaluated. The specific presentation of bifacial weakness as the initial symptom may be a characteristic feature of GBS in the context of recent COVID-19 vaccination. |*COVID-19[MESH] |*Guillain-Barre Syndrome/etiology[MESH] |*Influenza Vaccines/adverse effects[MESH] |COVID-19 Vaccines[MESH] |Humans[MESH] |SARS-CoV-2[MESH]Guillain-Barre syndrome after COVID-19 vaccination (epmc).pdf DeepDyve Pubget Overpricing